ZADH2 CRISPR/Cas9 KO Plasmid (h): sc-408358
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ZADH2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ZADH2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ZADH2 CRISPR/Cas9 KO Plasmid (h) | sc-408358 | 20 µg | $397.00 |
Overview
ZADH2 (zinc-binding alcohol dehydrogenase domain-containing protein 2) encodes a putative oxidoreductase featuring an alcohol dehydrogenase–like zinc-binding motif, suggesting a role in cellular redox chemistry and metabolism. As a member of a broader dehydrogenase/reductase landscape, ZADH2 is expected to influence cofactor-dependent enzymatic processes that intersect with lipid and aldehyde handling, oxidative stress responses, and mitochondrial or cytosolic metabolic homeostasis. Variation in redox and metabolic enzyme activity is frequently linked to altered proliferation, differentiation, and stress adaptation in human tissues, making ZADH2 a relevant target for mechanistic studies in metabolic rewiring and cell-state control. Ongoing investigation of ZADH2 expression and function across tissue contexts supports its use in pathway-focused research rather than a single disease-specific model.
ZADH2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ZADH2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ZADH2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ZADH2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ZADH2 protein expression.
This CRISPR knockout system enables efficient generation of ZADH2-deficient cell models for investigation of ZADH2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ZADH2 exon(s) critical for ZADH2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ZADH2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ZADH2 CRISPR/Cas9 KO Plasmid (h) and ZADH2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ZADH2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ZADH2 HDR Plasmid (h) and ZADH2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ZADH2 homology arms to support homology-directed repair at defined ZADH2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.